3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Endocrine
1
CNS
1
Conditions
Carcinoma, Renal Cell
8
von Hippel-Lindau Disease
3
Pheochromocytoma
2
Paraganglioma
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Ovarian Neoplasms
1
Neuroectodermal Tumors, Primitive
1
Neoplasm Metastasis
1
Metastatic Castration-Resistant Prostate Cancer
1
Kidney Neoplasms
1
Hemangioblastoma
1
Endometrial Neoplasms
1
Clear-cell metastatic renal cell carcinoma
1
Carcinoma
1
Breast Neoplasms
1
Adenoma, Islet Cell
1
Interventions
Temozolomide
3
Cyclophosphamide
3
Etoposide
2
ibrutinib
1
gallium Ga 68 dotatate
1
fludarabine
1
etoposide phosphate
1
belzutifan
1
Zoledronic Acid
1
Vincristine
1
Thiotepa
1
Tamoxifen
1
Standard of Care
1
Radiotherapy
1
ONC206
1
Nivolumab
1
Mesna
1
Isotretinoin
1
Hydrocortisone
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Eflornithine
1
Drug Therapy
1
Cisplatin
1
Celecoxib
1
Carboplatin
1
Blood Specimen Collection
1
Automobiles
1
1-methyltryptophan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neuroectodermal Tumors, Primitive
×
belzutifan
×
Clear all
NCT07167329
2025-09-11
BELIEVE-VHL
AC Camargo Cancer Center
Phase 2
Recruiting
100 enrolled